Masonic Cancer Center, University of Minnesota

Public and Patients

Researchers and Staff

A Comprehensive Cancer Center Designated by the National Cancer Institute

Home > Cancer Information > Pediatric Phase I/II Therapeutics Clinical Trials > Osteosarcoma, Ewing's, Other Bone Tumors/Sarcomas

Pediatric Phase I/II Therapeutics Clinical Trials
Osteosarcoma, Ewing's, Other Bone Tumors/Sarcomas

The following links go to the National Cancer Institute Web site clinical trials listings for health care professionals. If you would like to read descriptions of the trials written for patients, click on the "Patient Version" tab at the top of the NCI pages.

ADVL0221 Phase II Study of Ecteinascidin 743 in Pediatric Patients With Recurrent or Refractory Soft Tissue Sarcomas or Ewing's Sarcoma Family of Tumors

ADVL0413 A Phase I study of the raf kinase and receptor tyrosine kinase inhibitor Sorafenib in children with refractory solid tumors or refractory leukemias

ADVL0516 A Phase I Study of Dasatinib in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia

ADVL0612 Phase I Study of Sunitinib Malate in Pediatric Patients With Refractory Solid Tumors

ADVL0525 A Phase II Study of Pemetrexed in Children with Recurrent Malignancies

ADVL0712 Phase I Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 in Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid tumor

ADVL0714 Phase I Study of Aflibercept (VEGF-trap) in Pediatric Patients With Relapsed or Refractory Solid Tumors

A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720)

A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors